Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor α by inhibiting NF-κB signaling pathway

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Li, Chenghai ^a   Yang, Zhengfeng ^a   Zhai, Chunyan ^a   Qiu, Wenwei ^a   Li, Dali ^a   Yi, Zhengfang ^a   Wang, Lei ^a   Tang, Jie ^a   Qian, Min ^a   Luo, Jian ^a   Liu, Mingyao ^a,b  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; GELATINASE B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INTERCELLULAR ADHESION MOLECULE 1; MASLINIC ACID; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; TRITERPENE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG POTENTIATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; DNA MICROARRAY; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; NICK END LABELING; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950540096     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-73     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Koliopanos A, Avgerinos C, Paraskeva C, Touloumis Z, Kelgiorgi D, Dervenis C. Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2008, 7:345-356.
3. Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM. Molecular targeted therapies for pancreatic cancer. Am J Surg 2008, 196:430-441. 10.1016/j.amjsurg.2008.04.009, 2570700, 18718222.
4. Feldmann G, Maitra A. Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 2008, 10:111-122. 10.2353/jmoldx.2008.070115, 2259464, 18258927.
5. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20:1218-1249. 10.1101/gad.1415606, 16702400.
6. Diamantidis M, Tsapournas G, Kountouras J, Zavos C. New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. Curr Mol Med 2008, 8:12-37. 10.2174/156652408783565586, 18289011.
7. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008, 7:64. 10.1186/1476-4598-7-64, 2515336, 18652674.
8. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008, 68:1443-1450. 10.1158/0008-5472.CAN-07-5704, 18316608.
9. Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP 2007, 8:4-15.
10. Pilati P, Rossi CR, Mocellin S. Strategies to enhance the anticancer potential of TNF. Front Biosci 2008, 13:3181-3193. 10.2741/2919, 17981787.
11. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998, 10:573-580. 10.1016/S0952-7915(98)80226-4, 9794839.
12. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996, 334:1717-1725. 10.1056/NEJM199606273342607, 8637518.
13. Mocellin S, Pilati P, Nitti D. Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer. Curr Pharm Des 2007, 13:537-551. 10.2174/138161207780162926, 17348848.
14. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005, 16:35-53. 10.1016/j.cytogfr.2004.11.001, 15733831.
15. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756. 10.1038/nri1184, 12949498.
16. Sung B, Pandey MK, Ahn KS, Yi T, Chaturvedi MM, Liu M, Aggarwal BB. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood 2008, 111:4880-4891. 10.1182/blood-2007-10-117994, 2384122, 18349320.
17. Aladedunye FA, Okorie DA, Ighodaro OM. Anti-inflammatory and antioxidant activities and constituents of Platostoma africanum P. Beauv. Nat Prod Res 2008, 22:1067-1073. 10.1080/14786410802264004, 18780248.
18. Scalon Cunha LC, Andrade e Silva ML, Cardoso Furtado NA, Vinholis AH, Gomes Martins CH, da Silva Filho AA, Cunha WR. Antibacterial activity of triterpene acids and semi-synthetic derivatives against oral pathogens. Z Naturforsch [C] 2007, 62:668-672.
19. Sultana N, Lee NH. Antielastase and free radical scavenging activities of compounds from the stems of Cornus kousa. Phytother Res 2007, 21:1171-1176. 10.1002/ptr.2230, 17661332.
20. Liu J, Sun H, Duan W, Mu D, Zhang L. Maslinic acid reduces blood glucose in KK-Ay mice. Biol Pharm Bull 2007, 30:2075-2078. 10.1248/bpb.30.2075, 17978478.
21. Fernandez-Navarro M, Peragon J, Amores V, De La Higuera M, Lupianez JA. Maslinic acid added to the diet increases growth and protein-turnover rates in the white muscle of rainbow trout (Oncorhynchus mykiss). Comp Biochem Physiol C Toxicol Pharmacol 2008, 147:158-167. 10.1016/j.cbpc.2007.09.010, 17945540.
22. Reyes-Zurita FJ, Rufino-Palomares EE, Lupianez JA, Cascante M. Maslinic acid, a natural triterpene from Olea europaea L., induces apoptosis in HT29 human colon-cancer cells via the mitochondrial apoptotic pathway. Cancer Lett 2009, 273:44-54. 10.1016/j.canlet.2008.07.033, 18790561.
23. Martin R, Carvalho J, Ibeas E, Hernandez M, Ruiz-Gutierrez V, Nieto ML. Acidic triterpenes compromise growth and survival of astrocytoma cell lines by regulating reactive oxygen species accumulation. Cancer Res 2007, 67:3741-3751. 10.1158/0008-5472.CAN-06-4759, 17440087.
24. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870, 16724054.
25. Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, Chiao PJ. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005, 103:2485-2490. 10.1002/cncr.21075, 15861417.
26. Zheng L, Bidere N, Staudt D, Cubre A, Orenstein J, Chan FK, Lenardo M. Competitive control of independent programs of tumor necrosis factor receptor-induced cell death by TRADD and RIP1. Mol Cell Biol 2006, 26:3505-3513. 10.1128/MCB.26.9.3505-3513.2006, 1447428, 16611992.
27. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693. 10.1016/j.cell.2007.10.037, 18022363.
28. van Rossen ME, Hofland LJ, Tol MP, van Koetsveld PM, Jeekel J, Marquet RL, van Eijck CH. Effect of inflammatory cytokines and growth factors on tumour cell adhesion to the peritoneum. J Pathol 2001, 193:530-537. 10.1002/1096-9896(2000)9999:9999<::AID-PATH805>3.0.CO;2-O, 11276014.
29. Zhang Y, Gavriil M, Lucas J, Mandiyan S, Follettie M, Diesl V, Sum FW, Powell D, Haney S, Abraham R, Arndt K. IkappaBalpha kinase inhibitor IKI-1 conferred tumor necrosis factor alpha sensitivity to pancreatic cancer cells and a xenograft tumor model. Cancer Res 2008, 68:9519-9524. 10.1158/0008-5472.CAN-08-1549, 19010928.
30. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, Liu M. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 2008, 68:1843-1850. 10.1158/0008-5472.CAN-07-5944, 2587446, 18339865.
31. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007, 67:3853-3861. 10.1158/0008-5472.CAN-06-4257, 17440100.
32. Takada Y, Ichikawa H, Badmaev V, Aggarwal BB. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J Immunol 2006, 176:3127-3140.
33. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma . Neoplasma 2009, 56:56-62. 10.4149/neo_2009_01_56, 19152246.